Akums Drugs and Pharmaceuticals Ltd
Akums Drugs: Rs. 52.74 Cr Demand Notice from NPPA on Subsidiary
REGULATORY
▼ Concern Flagged
MEDIUM RISK
📅 Filed on BSE: 15 Oct 2026, 04:38 PM IST · BSE ID: d678e481-0c13-4604-b3d7-b126798b1090
View Original BSE Filing (PDF)
💡
In Simple Terms
A company subsidiary got a notice for selling a medicine at too high a price, potentially involving over Rs. 52 crore.
🤖 AI Summary
- Rs. 52,74,68,193 Demand Notice issued to Akums subsidiary by NPPA.
- Notice alleges excess Maximum Retail Price (MRP) on 'Lanol 1000 mg injection'.
- Pure and Cure Healthcare received notice dated October 13, 2026, on October 15, 2026.
- Akums' agreements state marketing entity is solely liable for DPCO provision violations.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Demand Notice Amount
Rs. 52,74,68,193/-
Demand Notice Date
October 13, 2026
Demand Notice Receipt Date
October 15, 2026
🏢 How This Affects the Company
This demand notice introduces uncertainty regarding compliance with drug pricing regulations, potentially impacting relationships with clients and regulatory standing.
A Rs. 52,74,68,193/- liability has been raised, although the company's agreements aim to shift this responsibility to the marketing client.
This event increases regulatory and compliance risk for the company and its subsidiary, particularly concerning drug pricing controls.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders; monitor company disclosures for further developments.
👤
Who Is Affected
All shareholders are affected due to the potential financial and regulatory implications of the demand notice.
🔍
Management Signal
Management's statement highlights reliance on contractual clauses for liability, signaling a strategy to contest or transfer the financial burden.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Response from Hetero Healthcare Limited to the demand notice.
Further communication from NPPA regarding the demand notice.
Company updates on the resolution of the pricing violation issue.
MEDIUM RISK
Significant demand notice amount and potential regulatory scrutiny due to pricing violations.
💡 Investor Takeaway
Akums Drugs' subsidiary received a Rs. 52,74,68,193/- demand notice from NPPA for alleged pricing violations. The company asserts its agreements hold the marketing client solely liable.
⚖️ Strengths & Concerns
⚠️ Concerns
- Rs. 52,74,68,193/- demand notice received by subsidiary for alleged MRP violations.
📅 Company Track Record
Akums' subsidiary faced a previous tax penalty issue in Gujarat, which was later cancelled by an appellate authority.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the total demand notice amount issued to Akums Drugs' subsidiary?
The National Pharmaceuticals Pricing Authority (NPPA) issued a demand notice of Rs. 52,74,68,193/- to Pure and Cure Healthcare Private Limited.
Why was the demand notice issued to Pure and Cure Healthcare Private Limited?
The notice was issued because the client, Hetero Healthcare Limited, allegedly fixed the Maximum Retail Price (MRP) of 'Lanol 1000 mg injection' in excess of prescribed limits.
When was the demand notice issued and received?
The demand notice was dated October 13, 2026, and was received by the company on October 15, 2026.
Does Akums Drugs hold liability for this demand notice?
Akums Drugs states that its supply agreements contain clauses making the marketing entity solely liable for violations of DPCO provisions and any resulting penalties.
Questions based on this BSE filing only. For information purposes.